October 9, 2021 – Eyenuk is proud to sponsor the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting this year in San Antonio, TX. Visit Eyenuk at booth #818 in the exhibit hall…
September 30, 2021 – Eyenuk is a proud sponsor of The Retina Society’s 54th Annual Scientific Meeting, being held at the Ritz-Carlton Chicago (Chicago, IL). Come visit us to learn more about our EyeArt® AI…
September 29, 2021 –Greg Russell, Eyenuk Head of Clinical Development, and William Dallman, Eyenuk Clinical Development Manager Eyenuk participated in the British Association of Retinal Screening Virtual Conference (BARS) 2021 on Friday, September 24th. Russell…
August 24, 2021 – Eyenuk is proud to announce the expansion of our customer base in Germany for automated diabetic retinopathy (DR) detection by the EyeArt® artificial intelligence (AI) system. Now the EyeArt AI system…
July 28, 2021 – HealthCare Dynamics International (HCDI), a minority, woman-owned, small business specializing in health care quality improvement and transformation, recently implemented the EyeArt® artificial intelligence (AI) system for community-based diabetic eye screening in…
The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.